Monte Rosa Therapeutics（GLUE）今日盘前股价大幅上涨50.91%，创下近期新高。
消息面上，该公司宣布其实验性药物MRT-8102在一项早期试验中表现出色，显著降低了高心血管疾病风险患者的炎症反应。数据显示，该药物能将患者的炎症指标CRP降低85%，几乎所有参与者在4周后都达到了安全水平。
此次试验招募了24名肥胖且CRP升高的患者，药物在所有剂量下均显示出有效性。公司计划今年晚些时候在动脉堵塞患者中开展更大规模的试验，进一步验证其疗效。这一积极进展增强了市场对公司药物开发前景的信心，推动了股价的强劲上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.